II. Indications
-
Human Immunodeficiency Virus (HIV)
- Pneumocystis carinii Pneumonia prophylaxis
- Pneumocystis carinii Pneumonia treatment
- Patients unable to tolerate Bactrim
- Babesiosis (off-label)
- Toxoplasmosis in HIV Infection (off-label)
III. Contraindications
- Creatinine Clearance <30 ml/minute/1.73m2
- Breast Feeding of infants under 11 lb (5 kg)
IV. Mechanism
- Synthetic hydroxynaphthoquinone with Antiprotozoal activity
- Blocks mitochondrial electron transport at complex 3 of the respiratory chain of Protozoa
- Inhibits Pyrimidine synthesis (and therefore Protozoal DNA synthesis)
V. Dosing: Pneumocystis carinii Pneumonia
- Adults (and children age >13 years)
- Prophylaxis: 1500 mg orally daily with food
- Treatment: 750 mg orally twice daily with food for 21 days
VI. Dosing: Toxoplasmosis in comorbid HIV Infection
- Atovaquone is taken in combination with either Sulfadiazine or pyrimethanine-leucovorin
- Adults (off-label)
- Acute: 1500 mg orally twice daily with food for 6 weeks or more
- Chronic: 750 to 1500 mg orally with food twice daily
VII. Dosing: Babesiosis (Mild to Moderate Disease, Off-Label Use)
- Taken in combination with Azithromycin (high dose Azithromycin if Immunocompromised)
- Adult: 750 mg orally every 12 hours with food
- Child: 20 mg/kg (up to 750 mg) orally every 12 hours with food for 7 to 10 days
VIII. Dosing: Malaria
- See Atovaquone/Proguanil (Malarone)
IX. Precautions: Poor absorption
- Take with food (fatty meal) to ensure absorption
- Up to 10% of patients still may not absorb Mepron
- Repeat dose if Vomiting occurs within one hour of treatment in adults (within 30 minutes for children)
- Tablets may be crushed and mixed with 10 ml water if unable to swallow tablets
X. Efficacy: HIV
XI. Adverse Effects
- Less dose-limiting adverse reactions than Bactrim
- Atovaquone: 7%
- Bactrim: 20%
- Rash
- Abdominal Pain
- Nausea or Vomiting
- Diarrhea
- Headache
- Mild Liver Function Test abnormalities
XII. Safety
- Pregnancy Category C
- Unknown safety in Lactation
- Contraindicated in Breast Feeding of infants under 11 lb (5 kg)
XIII. Drug Interactions
- Reduced plasma levels of Atovaquone (and decreased efficacy)
- Efavirenz (avoid)
- Rifampin (avoid)
- Rifabutin
- Rifapentine
- Tetracycline
- Metoclopramide (Reglan)
XIV. Resources
- Atovaquone Suspension (DailyMed)
XV. References
Images: Related links to external sites (from Bing)
Related Studies
atovaquone (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ATOVAQUONE 750 MG/5 ML SUSP | Generic | $1.22 per ml |
ATOVAQUONE-PROGUANIL 250-100 MG TABLET | Generic | $2.03 each |
ATOVAQUONE-PROGUANIL 62.5-25 | Generic | $0.63 each |
Ontology: Atovaquone (C0165603)
Definition (NCI) | A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death. |
Definition (CSP) | broad-spectrum antiparasitic drug found to be active against Pneumocystis carinii pneumonia in AIDS patients. |
Definition (MSH) | A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D053626 |
SnomedCT | 391793007, 108718008, 386899002 |
LNC | LP94829-6, MTHU031993 |
English | atovaquone, 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone, Atovaquone, 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione, atovaquone (medication), ATOVAQUONE, Atovaquone [Chemical/Ingredient], Atovaquone - chemical, Atovaquone - chemical (substance), Atovaquone (product), Atovaquone (substance) |
Portuguese | Atovaquona |
Spanish | Atovacuona, Atovaquona, atovacuona (producto), atovacuona (sustancia), atovacuona |
Russian | АТОВАКОН, ATOVAKON |
Italian | Atovaquone |
German | Atovaquon, 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinon, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinon |
French | Atovaquone, 2-(4-(4'-Chlorophényl)cyclohexyl)-3-hydroxy-1,4-naphtoquinone |
Czech | 2-(trans-4-(4-chlorfenyl)cyklohexyl)-3-hydroxy-1,4-naftochinon, atovachon, 2-(4-(4'-chlorfenyl)cyklohexyl)-3-hydroxy-1,4-naftochinon |
Finnish | Atovakvoni |
Japanese | アトバコン |
Swedish | Atovakvon |
Polish | Atowakon |
Ontology: Mepron (C0378468)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D053626 |
English | Mepron, Wellvone, Glaxo Wellcome brand of atovaquone, GlaxoSmithKline brand of atovaquone, atovaquone GlaxoSmithKline brand, mepron |
German | Wellvone, Mepron |
French | Malarone, Wellvone, Mepron |
Czech | Mepron |